Thyrocare Technologies Ltd

Thyrocare Technologies Limited has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 01, 2026, and will reopen 48 hours after the declaration of un-audited financial results for the quarter and half-year ended September 30, 2026. The specific date for the board meeting to consider these financial results will be communicated separately.

Thyrocare Technologies Limited announced the grant of 1,92,000 stock options to eligible employees under its Employee Stock Option Scheme. The options are granted at an exercise price of Rs. 10 per option. These options will vest over three years, with one-third vesting annually, subject to continued employment and other conditions. Employees can exercise the vested options within seven years from the vesting date. This move aims to incentivize and retain key talent within the organization.

Thyrocare Technologies Ltd announced the sale of its entire shareholding in its wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), to Trovera Healthcare Private Limited for approximately ₹141.4 crore. This divestment includes 1,11,11,000 equity shares, representing 100% of NHL's capital. The consideration comprises ₹59.5 crore in Compulsorily Convertible Preference Shares (CCPS) of Trovera and ₹81.9 crore in cash, subject to adjustments. The sale, approved by the Board and subject to shareholder approval, allows Thyrocare to focus on its core pathology business. NHL will cease to be a subsidiary post-transaction. The valuation was based on a report by V. B. Desai Financial Services Limited.

Thyrocare Technologies Ltd announced the approval by its Board of Directors to sell its entire stake in its wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), to Trovera Healthcare Private Limited for approximately ₹1414 crore. This divestment marks Thyrocare's exit from the radiology business to focus on its core pathology operations. The consideration includes ₹59.50 crore in Compulsorily Convertible Preference Shares (CCPS) of Trovera and ₹81.90 crore in cash, subject to adjustments. The company will acquire these CCPS as part of the deal. The transaction is subject to shareholder approval and regulatory clearances. NHL will cease to be a subsidiary post-completion.

Thyrocare Technologies Limited announced the sale of its entire shareholding in its wholly-owned subsidiary, Nueclear Healthcare Limited (NHL), to Trovera Healthcare Private Limited for approximately ₹1,414 crore. The divestment includes 1.11 crore equity shares, representing 100% of NHL. The consideration comprises Compulsorily Convertible Preference Shares (CCPS) in Trovera valued at ₹595 crore and cash of approximately ₹819 crore. This strategic move allows Thyrocare to focus on its core pathology business. The transaction is subject to shareholder and regulatory approvals.

Thyrocare Technologies Ltd has received a revised disclosure regarding promoter Docon Technologies Private Limited. The entire pledge on 7,94,69,696 equity shares of Thyrocare, created by Docon as security for NCDs issued by API Holdings Limited, has been fully released as of August 17, 2026. Subsequently, Docon was amalgamated with API Holdings Limited effective September 3, 2026, making API Holdings the successor entity. This filing updates the previous disclosure to reflect these changes.

API Holdings Limited has successfully completed the amalgamation of Docon Technologies Private Limited with itself, a process sanctioned by the National Company Law Tribunal (NCLT) on August 31, 2026. The amalgamation became effective on September 3, 2026, with the filing of the NCLT order with the Registrar of Companies. As a result, Docon's entire shareholding in Thyrocare Technologies Ltd, amounting to 8,12,00,000 equity shares (51.02% stake), has been transferred and vested with API Holdings by operation of law. This transaction does not alter the aggregate shareholding of Thyrocare's Promoter and Promoter Group.

Thyrocare Technologies Ltd has announced the completion of the amalgamation of Docon Technologies Private Limited with API Holdings Limited. The National Company Law Tribunal (NCLT), Mumbai Bench, sanctioned the scheme on August 31, 2026. The scheme became effective on September 3, 2026, with Docon's assets, liabilities, and undertakings vesting in API Holdings. Consequently, API Holdings now holds Docon's entire shareholding in Thyrocare, comprising 8,12,00,000 equity shares, representing 51.02% of the paid-up share capital. This transaction does not alter the aggregate shareholding of Thyrocare's promoter and promoter group.

Thyrocare Technologies Ltd announced that the National Company Law Tribunal (NCLT), Mumbai Bench, has sanctioned the Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited. The amalgamation, effective upon filing with the Registrar of Companies, will see Docon's assets and liabilities transferred to API. Docon's 51.02% stake in Thyrocare will be vested in API, resulting in no change to the aggregate shareholding of the Promoter and Promoter Group, which remains at 51.02%. API Holdings Limited will hold this stake directly post-amalgamation.

Thyrocare Technologies Ltd announced the complete discharge and release of transaction documents following the full redemption and repayment of Non-Convertible Debentures (NCDs) issued by API Holdings Limited, the ultimate holding company. These NCDs, aggregating to INR 1,700 crore, were secured by a pledge of equity shares held by Docon Technologies Private Limited in Thyrocare. The pledge has now been fully released, and all obligations under the NCDs and related transaction documents are discharged. This event has no impact on Thyrocare Technologies Limited.